Neal Rosen

54.5k total citations · 13 hit papers
255 papers, 34.8k citations indexed

About

Neal Rosen is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Neal Rosen has authored 255 papers receiving a total of 34.8k indexed citations (citations by other indexed papers that have themselves been cited), including 199 papers in Molecular Biology, 92 papers in Oncology and 38 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Neal Rosen's work include Melanoma and MAPK Pathways (56 papers), PI3K/AKT/mTOR signaling in cancer (53 papers) and Heat shock proteins research (44 papers). Neal Rosen is often cited by papers focused on Melanoma and MAPK Pathways (56 papers), PI3K/AKT/mTOR signaling in cancer (53 papers) and Heat shock proteins research (44 papers). Neal Rosen collaborates with scholars based in United States, United Kingdom and Canada. Neal Rosen's co-authors include David B. Solit, Andrea Basso, Poulikos I. Poulikakos, Laura Sepp‐Lorenzino, Sarat Chandarlapaty, Qing‐Bai She, Maurizio Scaltriti, Gideon Bollag, Gabriela Chiosis and José Baselga and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Neal Rosen

249 papers receiving 34.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

2006 2.0k citations Kathryn O’Reilly, Qing‐Bai She et al. Cancer Research profile →
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

2010 1.3k citations Poulikos I. Poulikakos, Neal Rosen et al. profile →
Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent

1997 1.2k citations Neal Rosen et al. profile →
BRAF mutation predicts sensitivity to MEK inhibition

2005 1.0k citations David B. Solit, Christine A. Pratilas et al. profile →
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

2011 890 citations Brett S. Carver, John Wongvipat et al. Cancer Cell profile →
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

2011 746 citations Sarat Chandarlapaty, Ayana Sawai et al. Cancer Cell profile →
Targeted drug delivery strategies for precision medicines

2021 738 citations Neal Rosen, Maurizio Scaltriti et al. profile →
Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function

2002 524 citations Andrea Basso, David B. Solit et al. profile →
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

2016 457 citations Piro Lito, Martha Solomon et al. Science profile →
Tumor adaptation and resistance to RAF inhibitors

2013 417 citations Piro Lito, Neal Rosen et al. profile →
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

2012 410 citations Piro Lito, Christine A. Pratilas et al. Cancer Cell profile →
Therapy-induced tumour secretomes promote resistance and tumour progression

2015 364 citations Neal Rosen et al. profile →
BRAF — a tumour-agnostic drug target with lineage-specific dependencies

2024 57 citations Aphrothiti J. Hanrahan, Neal Rosen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Neal Rosen United States	100	24.7k	12.2k	5.7k	4.2k	3.5k	255	34.8k
David B. Solit United States	82	15.6k 0.6×	10.6k 0.9×	5.6k 1.0×	4.8k 1.1×	3.5k 1.0×	365	26.2k
Keith T. Flaherty United States	92	23.3k 0.9×	24.8k 2.0×	6.3k 1.1×	5.7k 1.3×	3.2k 0.9×	518	39.7k
Nathanael S. Gray United States	104	30.5k 1.2×	10.9k 0.9×	4.9k 0.9×	3.0k 0.7×	2.7k 0.8×	476	42.2k
William R. Sellers United States	82	22.7k 0.9×	13.6k 1.1×	10.5k 1.8×	7.1k 1.7×	2.6k 0.7×	165	34.8k
Olli Kallioniemi Finland	99	20.2k 0.8×	9.7k 0.8×	7.4k 1.3×	11.3k 2.7×	4.5k 1.3×	428	36.3k
Charles L. Sawyers United States	99	24.8k 1.0×	12.3k 1.0×	15.9k 2.8×	9.3k 2.2×	3.4k 1.0×	266	53.4k
Nikolaus Schultz United States	67	24.8k 1.0×	11.7k 1.0×	9.9k 1.8×	12.8k 3.0×	4.2k 1.2×	228	39.0k
Frank McCormick United States	118	42.8k 1.7×	14.4k 1.2×	4.1k 0.7×	5.6k 1.3×	3.0k 0.9×	381	57.5k
Carlos L. Arteaga United States	101	19.8k 0.8×	18.4k 1.5×	7.2k 1.3×	6.4k 1.5×	2.4k 0.7×	432	34.7k
Richard Marais United Kingdom	77	18.6k 0.8×	9.1k 0.7×	1.5k 0.3×	3.3k 0.8×	2.4k 0.7×	229	25.7k

Countries citing papers authored by Neal Rosen

Since Specialization

Citations

This map shows the geographic impact of Neal Rosen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neal Rosen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neal Rosen more than expected).

Fields of papers citing papers by Neal Rosen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neal Rosen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neal Rosen. The network helps show where Neal Rosen may publish in the future.

Co-authorship network of co-authors of Neal Rosen

This figure shows the co-authorship network connecting the top 25 collaborators of Neal Rosen. A scholar is included among the top collaborators of Neal Rosen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neal Rosen. Neal Rosen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jhaveri, Komal, Joshua Z. Drago, Payal D. Shah, et al.. (2021). A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA -Mutated HER2-Positive Metastatic Breast Cancer. Clinical Cancer Research. 27(14). 3867–3875. 26 indexed citations

Smith, Alison, Emanuela Ferraro, Anton Safonov, et al.. (2021). HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nature Communications. 12(1). 6667–6667. 61 indexed citations

Lito, Piro, Martha Solomon, Lian‐Sheng Li, Rasmus Hansen, & Neal Rosen. (2016). Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 351(6273). 604–608. 457 indexed citations breakdown →

Jhaveri, Komal, Sarat Chandarlapaty, Neil M. Iyengar, et al.. (2015). Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors. Clinical Breast Cancer. 16(4). 276–283. 10 indexed citations

Yaeger, Rona, Andrea Cercek, Eileen M. O’Reilly, et al.. (2015). Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF -Mutant Metastatic Colorectal Cancer Patients. Clinical Cancer Research. 21(6). 1313–1320. 221 indexed citations

Hyman, David M., Eli L. Diamond, Cecile Rose T. Vibat, et al.. (2014). Prospective Blinded Study of BRAF V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. Cancer Discovery. 5(1). 64–71. 84 indexed citations

Will, Marie, Alice Can Ran Qin, Weiyi Toy, et al.. (2014). Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS–ERK Signaling. Cancer Discovery. 4(3). 334–347. 158 indexed citations

Sakr, Rita A., Britta Weigelt, Sarat Chandarlapaty, et al.. (2014). PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ —Implications for Progression to Invasive Breast Carcinoma. Clinical Cancer Research. 20(9). 2326–2337. 39 indexed citations

Ishii, Nobuya, Naoki Harada, Eric W. Joseph, et al.. (2013). Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity. Cancer Research. 73(13). 4050–4060. 128 indexed citations

10.

Chandarlapaty, Sarat, Rita A. Sakr, Dilip D. Giri, et al.. (2012). Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer. Clinical Cancer Research. 18(24). 6784–6791. 166 indexed citations

11.

Carver, Brett S., John Wongvipat, Haley Hieronymus, et al.. (2011). Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer. Cancer Cell. 19(5). 575–586. 890 indexed citations breakdown →

12.

Hanrahan, Aphrothiti J., Nikolaus Schultz, Maggie L. Westfal, et al.. (2011). Genomic Complexity and AKT Dependence in Serous Ovarian Cancer. Cancer Discovery. 2(1). 56–67. 88 indexed citations

13.

Rodrik-Outmezguine, Vanessa, Sarat Chandarlapaty, Nen C. Pagano, et al.. (2011). mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling. Cancer Discovery. 1(3). 248–259. 342 indexed citations

14.

Halilovic, Ensar, Qing‐Bai She, Qing Ye, et al.. (2010). PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling. Cancer Research. 70(17). 6804–6814. 133 indexed citations

15.

Pratilas, Christine A., Aphrothiti J. Hanrahan, Ensar Halilovic, et al.. (2008). Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer. Cancer Research. 68(22). 9375–9383. 195 indexed citations

16.

Solit, David B., Iman Osman, David Polsky, et al.. (2008). Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma. Clinical Cancer Research. 14(24). 8302–8307. 146 indexed citations

17.

O’Reilly, Kathryn, Qing‐Bai She, David B. Solit, et al.. (2006). mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt. Cancer Research. 66(3). 1500–1508. 2037 indexed citations breakdown →

18.

Grbovic, Olivera M., Andrea Basso, Ayana Sawai, et al.. (2005). V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proceedings of the National Academy of Sciences. 103(1). 57–62. 228 indexed citations

19.

Smith‐Jones, Peter, David B. Solit, Timothy Akhurst, et al.. (2004). Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nature Biotechnology. 22(6). 701–706. 228 indexed citations

20.

Basso, Andrea, David B. Solit, Pamela N. Münster, & Neal Rosen. (2002). Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene. 21(8). 1159–1166. 217 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact